17,261 trials
Smoking · Smoking Cessation
Primary: Mean Change From Baseline in Nicotine Cravings VAS Scores in Light Smokers — -15.40; -8.17; -24.42; -17.26 Score on a scale — p=0.0643
Hepatitis B
Primary: Qualitative Seroresponsiveness to Hepatitis B Surface Antigen — 41; 52; 6; 3 Participants — p=0.2954
Multiple Sclerosis
Primary: Number of Participants With Any Adverse Event — 8; 10; 7; 3 participants
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants
Crohn's Disease
Primary: CDAI Clinical Response -100 at Week 8 — 19; 11 Participants
Brittle Nail Syndrome
Primary: • Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails. — 10; 11 patients
Cocaine Dependence
Primary: Single Item Craving Test Session Difference Scores — -25.0; -10.5 units on a scale
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) — 40 percentage of participants
Renal Cell Carcinoma
Primary: Progression-free Survival — 1.7 months
Esophageal Cancer
Primary: Pathologic Complete Response (pCR) Rate — 18 Participants
Ovarian Neoplasms
Primary: Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment — 386; 478 Days — p=0.655
Constipation · Diabetes Mellitus · Colonic Transit
Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01
Breast Cancer
Primary: Pathologic Complete Response — 23 Participants
Ovarian Cancer
Primary: Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine…
Type 1 Diabetes Mellitus
Primary: Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity — 176; 195 mg/dl